Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer

International Journal of Molecular Sciences(2021)10.3390/ijms22105207Source: DataRank Database

Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer is a research paper published in International Journal of Molecular Sciences (2021). On theSindex it has a DataRank of 0. It has been cited 73 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access73 citations

Download PDF

Cite:

Linked data & code

arrayexpress nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 5.43)OA: goldTopics (93)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Jinming Yang ORCID,Nabil Saleh ORCID,Sheau‐Chiann Chen ORCID,Gregory D. Ayers ORCID,Vandana G. Abramson ORCID

Live enrichment

PubMed:34069042 PMC:PMC8156389 OpenAlex:https://openalex.org/W3162666542

National Cancer Institute

Grant: CA34590

National Institutes of Health

Grant: CA243326

VA SRCS Award

Grant: IK6BX005225

VA MERIT Award

Grant: 101BX002301

BLRD VA

Grant: I01 BX002301

NCI NIH HHS

Grant: R01 CA243326

National Institutes of Health

Grant: 5R01CA034590-29

Chemokine Receptor Studies: Defining the Dynamics of the Chemosynapse

National Institutes of Health

Grant: 5R01CA243326-05

Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway

National Institutes of Health

Grant: 5IK6BX005225-04

BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)

National Institutes of Health

Grant: 3P30CA068485-23S2

Cancer Center Support Grant

FWCI

5.43

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/1422-0067/22/10/5207/pdf?version=1620989864

publisherhttps://www.mdpi.com/1422-0067/22/10/5207/pdf?version=1620989864

publisherhttps://www.mdpi.com/1422-0067/22/10/5207/pdf

journalhttps://doi.org/10.3390/ijms22105207

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34069042

Fields of Study

Cancer Immunotherapy and BiomarkersPI3K/AKT/mTOR signaling in cancerHistone Deacetylase Inhibitors Research0301 basic medicine03 medical and health sciencesAnimalsFemaleHumansAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCell Line, TumorGranulocytesImmune Checkpoint InhibitorsMice, Inbred C57BLMolecular Targeted TherapyMorpholinesPaclitaxelPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPyrimidinesQuinazolinesThiazolesTOR Serine-Threonine KinasesTreatment OutcomeTriazinesTumor MicroenvironmentXenograft Model Antitumor AssaysMice

MeSH Terms

Phosphoinositide-3 Kinase InhibitorsImmune Checkpoint InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleGranulocytesHumansMice, Inbred C57BLMorpholinesPyrimidinesQuinazolinesThiazolesTriazinesTreatment OutcomePaclitaxelPhosphatidylinositol 3-KinasesXenograft Model Antitumor AssaysCell Line, TumorMiceTOR Serine-Threonine KinasesMolecular Targeted TherapyTumor Microenvironment

Keywords

PI3K/AKT/mTOR pathwayCancer researchImmune systemCD8CancerGrowth inhibitionBreast cancerTriple-negative breast cancerMedicinePharmacologyBiologyChemistryImmunologyCell growthInternal medicineSignal transductionCell biologyBiochemistryCytotoxic T cellsPi3k/mtorImmune Checkpoint InhibitorPaclitaxelMorpholinesBreast NeoplasmsArticlePhosphatidylinositol 3-KinasesCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsAnimalsHumansMolecular Targeted TherapyImmune Checkpoint InhibitorsPhosphoinositide-3 Kinase InhibitorsTriazinesTOR Serine-Threonine KinasesMice, Inbred C57BLThiazolesPyrimidinesTreatment OutcomeQuinazolinesFemaleGranulocytes

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 4 of Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

10.6084/m9.figshare.23751950.v1figshare

10.6084/m9.figshare.23751950figshare

Additional file 15 of Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

10.6084/m9.figshare.23751983.v1figshare

10.6084/m9.figshare.23751983figshare

Additional file 17 of Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

10.6084/m9.figshare.23751989.v1figshare

Additional file 16 of Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

10.6084/m9.figshare.23751986figshare

10.6084/m9.figshare.23751986.v1figshare

10.6084/m9.figshare.23751989figshare

Additional file 13 of Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

10.6084/m9.figshare.23751977.v1figshare

Additional file 14 of Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

10.6084/m9.figshare.23751980figshare

10.6084/m9.figshare.23751977figshare

Additional file 12 of Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

10.6084/m9.figshare.23751974.v1figshare

10.6084/m9.figshare.23751980.v1figshare

Additional file 11 of Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

10.6084/m9.figshare.23751971figshare

Additional file 10 of Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

10.6084/m9.figshare.23751968figshare

10.6084/m9.figshare.23751971.v1figshare

10.6084/m9.figshare.23751974figshare

10.6084/m9.figshare.23751968.v1figshare

Additional file 7 of Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

10.6084/m9.figshare.23751959figshare

10.6084/m9.figshare.23751959.v1figshare